3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Automobiles
3
fludarabine
2
Sirolimus
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Cyclophosphamide
2
trametinib
1
sonidegib
1
ripretinib
1
ribociclib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
keyhole-limpet hemocyanin
1
interferon gamma-1b
1
guadecitabine
1
fludarabine phosphate
1
Vorinostat
1
Topotecan
1
Tetrahydrouridine
1
Tetanus Toxoid
1
Stem Cell Transplantation
1
Simvastatin
1
Photochemotherapy
1
Oncolytic Virotherapy
1
Mesna
1
Melphalan
1
Interferon-gamma
1
Immunotherapy
1
Filgrastim
1
Dihematoporphyrin Ether
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasms, Germ Cell and Embryonal
×
Oncolytic Virotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled